Statistics · 2026 · Stocks

Healthcare Stock Statistics (2026)

Health care is the fourth-largest of the 11 sectors in the S&P 500, at 9.1% of the index by weight, as of October 1, 2026. Its 60 companies hold $6.3 trillion in market value and 19.6% of the revenue of the 497 companies WealthyBud tracks. Eli Lilly (LLY) is the largest, at $1.07T. The median company earns a 13.13% net margin.

Key takeaways

How big is the health care sector in the S&P 500?

Health care is the fourth-largest of the 11 sectors in the S&P 500, with a 9.1% weight in the SPDR S&P 500 ETF holdings file on October 1, 2026. Its 60 companies are worth $6.25 trillion in total market value, 8.9% of the 497 companies with fundamentals in WealthyBud’s data.

1. Health care is 9.1% of the S&P 500 by index weight

Index weight comes from State Street’s SPY holdings file for October 1, 2026. The 60 companies sum to 9.1% (WealthyBud data · October 2, 2026).

2. Health care holds $6.3 trillion, 8.9% of total market value

The 60 companies add up to $6.25 trillion out of $70.0 trillion for 497 companies. This market-cap share differs from the 9.1% index weight because index weights follow S&P’s methodology, cover all 501 constituents (not 497) and date from October 1, 2026, not October 2, 2026 (WealthyBud data · October 2, 2026).

3. Health care earns 8.9% of net income on 19.6% of revenue

The sector reported $3.54 trillion in revenue and $0.20 trillion in net income in each company’s latest fiscal year. WealthyBud’s calculation shows its profit share is 0.45 times its revenue share, and health insurers alone book 31.7% of sector revenue at a median 2.7% margin (WealthyBud data · October 2, 2026).

4. State Street’s health care index has 60 holdings, matching our 60 companies

The State Street XLV fund page lists 60 holdings under its index characteristics, and XLV tracks the health care sector of the S&P 500. That equals the 60 companies in WealthyBud’s count.

Which health care companies are the largest?

Eli Lilly is the largest health care company, worth $1.07T, followed by Johnson & Johnson at $616.1B and AbbVie at $462.7B. The ten largest hold 60.8% of the sector’s market value. The table shows each company’s revenue, net margin and P/E.

5. The top three are 34.4% of sector market value

Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV) carry 3.0% of the S&P 500’s index weight and hold 34.4% of Health Care market cap (WealthyBud data · October 2, 2026).

The 10 largest Health Care companies in the S&P 500 by market value, latest fiscal-year revenue, net margin and price-to-earnings ratio, as of October 2, 2026
CompanyMarket capRevenueNet marginP/E
Eli Lilly (LLY)$1.07T$65.2B31.7%52.0
Johnson & Johnson (JNJ)$616.1B$94.2B28.5%23.0
AbbVie (ABBV)$462.7B$61.2B6.9%109.5
Merck (MRK)$354.0B$65.0B28.1%19.4
UnitedHealth Group (UNH)$331.9B$447.6B2.7%27.5
Thermo Fisher Scientific (TMO)$241.5B$44.6B15.0%36.0
Amgen (AMGN)$217.6B$36.8B21.0%28.2
Gilead Sciences (GILD)$179.0B$29.4B28.9%21.0
Abbott Laboratories (ABT)$169.4B$44.3B14.7%26.0
Pfizer (PFE)$156.9B$62.6B12.4%20.2
Stocks hub

See fundamentals and Investor Scores for 103 large caps

Open stocks

How profitable are health care companies?

The median Health Care company keeps 13.13% of revenue as net income, above the 12.92% median for the S&P 500. Among the 28 health care companies that report gross profit, the median gross margin is 59.7%. 5 of 60 health care companies lost money in their latest fiscal year.

6. Median net margin: 13.13% for health care, 12.92% for the index

Net margin is GAAP net income divided by revenue for each company’s latest fiscal year, so it includes non-operating gains and losses. The health care median covers 60 companies and the index median covers 497. (WealthyBud data · October 2, 2026).

7. Median gross margin: 59.7% for health care, 45.1% for the index

Many companies do not report gross profit. The health care median covers 28 of 60 companies and the index median covers 186 (WealthyBud data · October 2, 2026).

8. 5 of 60 health care companies reported a net loss

BAX, CNC, CRL, MRNA, and VTRS had negative net income in the latest fiscal year. The other 55 were profitable. CRL made $25.2M in operating income but lost $144.3M for shareholders after non-operating items, taxes and noncontrolling interests totaling $169.5M, including $107.0 million of interest expense. (WealthyBud data · October 2, 2026)

Among the 36 health care companies with at least $10 billion in revenue, these five had the highest GAAP net margins, which include non-operating gains and losses:

  1. Vertex Pharmaceuticals (VRTX) earned a 32.9% net margin on $12.0B of revenue.
  2. Eli Lilly (LLY) earned a 31.7% net margin on $65.2B of revenue.
  3. Regeneron Pharmaceuticals (REGN) earned a 31.4% net margin on $14.3B of revenue.
  4. Gilead Sciences (GILD) earned a 28.9% net margin on $29.4B of revenue.
  5. Johnson & Johnson (JNJ) earned a 28.5% net margin on $94.2B of revenue.

REGN’s net income of $4.5B exceeds its $3.6B of operating income. Its 10-K reports $1.65 billion of non-operating income, including $955.6 million of gains on equity securities. WealthyBud’s data has no operating income for LLY and JNJ, so it cannot check those.

How expensive are health care stocks?

The median health care stock trades at 27.9 times earnings, above the 25.2 median for the S&P 500. Its median price-to-sales ratio is 3.4, versus 3.3 for the index. The median dividend yield among payers with a yield is 1.21%, below the index’s 1.88%.

9. Median P/E: 27.9 for health care, 25.2 for the index

P/E here is market cap divided by latest-fiscal-year net income, for companies with positive earnings and a P/E. The health care median covers 54 companies and the index median covers 461. The 5 loss-makers have no P/E, and BDX is profitable but has its P/E withheld around a spin-off. (WealthyBud data · October 2, 2026).

10. 7 of 54 health care stocks with a P/E trade above 50 times earnings

ABBV, CVS, LLY, RVTY, TECH, WAT, and WST sit above that line. A P/E above 50 means investors pay more than $50 for each $1 of last year’s profit (WealthyBud data · October 2, 2026).

11. 37 of 60 health care companies pay a dividend

Their median yield is 1.21% across the 36 with a yield, against 1.88% among the 362 index companies with a yield. BDX is counted as a payer but has no yield shown because dividends predate a spin-off. (WealthyBud data · October 2, 2026).

How fast is health care revenue growing?

The median Health Care company grew revenue 7.1% in its latest fiscal year, above the 6.9% index median. 5 of 60 health care companies grew revenue more than 20%, and 7 reported lower revenue. Over three years the median compound rate was 5.5% a year.

12. Median revenue growth: 7.1% for health care, 6.9% for the index

Growth compares latest fiscal-year revenue with the year before. The latest year is 2025 and 2026 depending on the company (WealthyBud data · October 2, 2026).

13. 5 of 60 health care companies grew revenue by more than 20%

The fastest were Eli Lilly (LLY) at 45%, Humana (HUM) at 32%, and Insulet (PODD) at 31% (WealthyBud data · October 2, 2026).

How do pharma, devices and insurers compare?

Health insurers book 31.7% of sector revenue, $1.12 trillion across 5 companies, but keep a median 2.7% of it. The 16 pharma and biotech companies earn a median 18.0% on $0.57 trillion. The 15 device makers earn 13.2%. The groups follow SEC industry codes.

Health Care companies in the S&P 500 by SEC industry code: company count, latest fiscal-year revenue, market cap and median net margin, as of October 2, 2026
GroupSEC ruleCompaniesRevenueMarket capMedian net margin
Pharma & biotechSIC 2834, 283616$570.0B$3.73T18.0%
Devices & instrumentsSIC 3841, 3842, 384515$173.4B$688.3B13.2%
Health insurersSIC 63245$1.12T$564.1B2.7%
Other health careall other SIC codes24$1.67T$1.28T9.0%

14. Pharma and biotech: 16 companies, 18.0% median net margin

The group uses SEC codes 2834 (pharmaceutical preparations) and 2836 (biological products). It holds $3.73 trillion in market cap, 59.6% of the sector. The median P/E is 24.1 across 14 companies with a P/E. Code 2834 is broad: it includes ABT and ZTS alongside traditional drug makers (WealthyBud data · October 2, 2026).

15. Health insurers: 5 companies, $1.12 trillion in revenue

CI, CNC, ELV, HUM, and UNH use SEC code 6324 and earn a median 2.7% net margin. Their combined revenue is 2.0 times that of the 16 pharma and biotech companies. CVS files under retail drug stores (code 5912), so the rule places it in the other group (WealthyBud data · October 2, 2026).

16. Devices and instruments: 15 companies, 13.2% median net margin

The group uses SEC codes 3841, 3842 and 3845 (medical instruments, surgical appliances and electromedical apparatus). Median P/E is 25.9. Revenue totals $0.17 trillion (WealthyBud data · October 2, 2026).

17. The FDA approved 46 novel drugs in 2025

The FDA’s Center for Drug Evaluation and Research says it approved 46 new drugs never before approved or marketed in the U.S. in 2025, which it calls “novel” drugs, per its novel drug approvals page. This page does not test how approvals relate to stock prices.

18. Healthcare jobs: 1.9 million openings a year through 2035

The Bureau of Labor Statistics projects employment in healthcare occupations to grow “much faster than the average for all occupations” from 2025 to 2035, with about 1.9 million openings a year, per its Occupational Outlook Handbook. Median pay for healthcare practitioners and technical occupations was $86,530 in May 2025, against $50,980 for all occupations; healthcare support occupations paid $38,340. These figures cover all employers.

What this means for investors

Health care is not one business. Insurers earn a median 2.7% margin and drug makers 18.0%, so sector averages hide large gaps. The healthcare ETF statistics show how funds such as XLV package the sector.

The top three set the sector’s tone. Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV) hold 34.4% of sector market value. Their results drive sector-wide moves.

Valuation sits above the index. A 27.9 median P/E against 25.2 for the index leaves less room for an earnings miss. Compare income-oriented sectors in the consumer staples stock statistics.

Check each company, not the label. Our stocks hub and the largest companies statistics show fundamentals company by company.

More Stocks statistics

Frequently asked questions

How much of the S&P 500 is health care?
Health care is 9.1% of the S&P 500 by index weight, based on the SPDR S&P 500 ETF holdings file for October 1, 2026, which makes it the fourth-largest of 11 sectors. By total market value, its 60 companies hold 8.9% of the 497 S&P 500 companies WealthyBud tracks, a slightly different measure.
What is the largest health care stock in the S&P 500?
Eli Lilly (LLY) is the largest health care company, with a market value of $1.07T as of October 2, 2026. Johnson & Johnson (JNJ) ranks second at $616.1B, and AbbVie (ABBV) is third at $462.7B. Together the three hold 34.4% of the sector’s market value.
Are health care stocks expensive?
Slightly. The median health care stock trades at 27.9 times net income, against 25.2 for the median S&P 500 stock, and 7 of 54 health care companies with a P/E trade above 50 times. Median P/E runs from 21.2 for health insurers to 31.7 for other health care. Price-to-earnings uses past profit, so it does not predict returns.
Which health care industry is most profitable?
Pharma & biotech earns the highest median net margin among the four SEC-code groups, at 18.0%. The lowest is health insurers, at 2.7%, though insurers book $1.12 trillion in revenue. In order: pharma & biotech 18.0%, devices & instruments 13.2%, other health care 9.0%, health insurers 2.7%. Margins are latest-fiscal-year medians.
Do health care stocks pay dividends?
Most do. 37 of 60 health care companies pay a dividend, with a median yield of 1.21%, against 1.88% for the 362 index companies with a yield. Yield is the latest annual dividend per share divided by price, so it moves with the stock.
Figures on this page combine WealthyBud’s own datasets (as of October 2, 2026; index weights as of October 1, 2026; each company’s fundamentals are from its latest fiscal year, which ends at different dates) with cited public sources, as noted per statistic. This is a demonstration research page, not investment advice.

Darius Okafor Healthcare Sector Analyst

Darius Okafor is a healthcare sector analyst who covers pharmaceutical, biotech and healthcare-services equities, focusing on revenue durability and margin trends. He builds his coverage from public SEC filings and FDA disclosures.

Editorial persona: WealthyBud bylines are editorial personas, not real individuals. Pages are produced by the WealthyBud research team from the public data cited on each page.